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Introduction: Paroxysmal kinesigenic dyskinesia is characterized by sudden attacks of involuntary movements. It is
often misdiagnosed clinically as psychogenic illness, which distresses the patients to a great extent. A correct
diagnosis will improve the quality of life in patients with paroxysmal kinesigenic dyskinesia because treatment with
low doses of anticonvulsants is effective for eliminating the clinical manifestations. Paroxysmal kinesigenic
dyskinesia can occur independently of or concurrently with benign infantile convulsion. Identification of PRRT2 as
the causative gene of benign infantile convulsion and paroxysmal kinesigenic dyskinesia allows genetic
confirmation of the clinical diagnosis.
Case presentation: We describe the clinical features of a Japanese family with either paroxysmal kinesigenic
dyskinesia or benign infantile convulsion. A PRRT2 missense mutation (c.981C > G, p.Ile327Met) was identified in two
patients with benign infantile convulsion and three patients with paroxysmal kinesigenic dyskinesia as well as in
two unaffected individuals. Allowing incomplete penetrance in the mutation carriers, this mutation co-segregated
completely with the phenotype. The patients with paroxysmal kinesigenic dyskinesia had been misdiagnosed with
psychogenic illness for many years. They were correctly diagnosed with paroxysmal kinesigenic dyskinesia when
their children visited a pediatrician for benign infantile convulsion. Treatment with carbamazepine controlled their
involuntary movements completely.
Conclusions: Paroxysmal kinesigenic dyskinesia is a treatable movement disorder that is often misdiagnosed
clinically as psychogenic illness. It is important to note that two clinically distinct disorders, benign infantile
convulsion and paroxysmal kinesigenic dyskinesia, are allelic conditions caused by PRRT2 mutations. Paroxysmal
kinesigenic dyskinesia should be suspected in families with a child with benign infantile convulsion.
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Paroxysmal dyskinesias are episodic movement disorders
characterized by sudden attacks of involuntary move-
ments, such as dystonia, choreoathetosis, and ballism.
Most patients are neurologically normal between the
attacks and remain conscious through these attacks.
On the basis of the events that trigger the abnormal
movements, paroxysmal dyskinesias are subdivided in-
to paroxysmal kinesigenic dyskinesia (PKD), paroxysmal
exercise-induced dyskinesia (PED), and paroxysmal non-* Correspondence: satoru5p@asahikawa-med.ac.jp
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article, unless otherwise stated.kinesigenic dyskinesia (PNKD) [1,2]. In patients with
PKD, the attacks of abnormal movements are triggered by
sudden voluntary movements and last less than 1 minute
[3]. The attacks from PED are caused by prolonged exer-
cise and disappear after cessation of physical exercise [4].
PED attacks last between 5 to 30 minutes. By contrast, in
patients with PNKD, the attacks occur spontaneously but
may be exacerbated by alcohol or caffeine consumption,
emotional stress, and fatigue [5]. PNKD attacks last mi-
nutes to hours and are typically longer than PKD attacks.
Most cases of PKD are familial and inherited in an auto-
somal dominant trait.
PRRT2 on chromosome 16 (16p11.2), which encodes
the Proline-rich transmembrane protein 2 (PRRT2), hasntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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Figure 1 A familial case with benign infantile convulsion and
paroxysmal kinesigenic dyskinesia and PRRT2 mutation. A:
Affection status for benign infantile convulsion and paroxysmal
kinesigenic dyskinesia are as noted. Underlined pedigree numbers
denote individuals whose deoxyribonucleic acid (DNA) was available
and who were analyzed in the present study. Asterisks denote
PRRT2 mutation carriers. B: Automated DNA sequencing using the
polymerase chain reaction product from the patients with either
benign infantile convulsion or paroxysmal kinesigenic dyskinesia
showed a C-to-G transition at nucleotide 981 in exon 3 of PRRT2
(NCBI accession NM_145239.2), as indicated by the arrow, which
resulted in an isoleucine-to-methionine substitution at amino acid
position 327 (p.Ile327Met). C. BclI digestion of the exon 3 polymerase
chain reaction product showed additional fragments (328bp and
137bp) in two members with benign infantile convulsion (III-2 and
III-3) and three members with paroxysmal kinesigenic dyskinesia
(II-2, II-3, and II-6) as well as in two unaffected members (I-2 and II-5),
which resulted from a C-to-G transition creating a new BclI
restriction site. These additional fragments were observed with
the wild-type fragment (465bp), confirming the heterozygous
mutation. Abbreviations: BIC, benign infantile convulsion; paroxysmal
kinesigenic dyskinesia, PKD; bp, base pairs; Val, valine; Leu, leucine; Ile,
isoleucine; Met, methionine.
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precise role in PKD remains unclear [6]. PKD can occur
independently of or concurrently with benign infantile
convulsion (BIC) that is characterized by nonfebrile con-
vulsions with onset between 3 and 12 months of age and
favorable outcome with normal psychomotor develop-
ment [7]. Typical seizures are focal with or without sec-
ondary generalization and usually occur in clusters.
The diagnosis of PKD is based on the clinical features
and the correct diagnosis has implications for treatment
and prognosis. However, PKD is often misdiagnosed
clinically as epilepsy or psychogenic illness. Recent gen-
etic discoveries will increase the chances of a correct
diagnosis and contribute to elucidating the pathophysi-
ology of this disease. Here we report the clinical features
of familial cases with either BIC or PKD. The PRRT2
mutation identified in the present study has been re-
ported in a patient with BIC without PKD [8].
Case presentation
Nine individuals of a Japanese family spanning three
generations participated in the study. A detailed family
history was obtained by interviewing each family mem-
ber. Five members had either BIC (Patients 1 and 2, as de-
scribed below) or PKD (Patients 3, 4, and 5) (Figure 1A).
No participant had both PKD and BIC.
Patient 1 (III-2): a boy, now aged 7 years, experienced
three afebrile seizures within 1 week at the age of 7
months. The seizures were characterized by a loss of
consciousness and hypotonia and lasted from 1 to 3 mi-
nutes. His growth and developmental milestones were
normal. Interictal electroencephalography (EEG) and cra-
nial computed tomography (CT) revealed normal findings.
He was treated with carbamazepine until 2 years of age,
and the seizures disappeared and did not reoccur after
cessation of the treatment. He has not shown any abnor-
mal paroxysmal movements so far.
Patient 2 (III-3): a boy, now aged 5 years and the
younger brother of Patient 1, presented with generalized
tonic–clonic seizures that occurred in clusters at 7 months
of age. He had normal neurological development. Inte-
rictal EEG and cranial CT findings were normal. He was
started on carbamazepine and achieved complete seizure
control. After cessation of treatment at 2 years of age, he
has experienced neither seizure recurrences nor paroxys-
mal dyskinesias.
Patient 3 (II-2): a woman who had no history of in-
fantile convulsions. At 12 years of age, she presented
with abnormal paroxysmal movements occurring several
times a day. These episodes were triggered by sudden
voluntary movement, such as standing up from a chair,
or by emotional stress, for example, when she was asked
to write on the blackboard at school. The involuntary
movements consisted of choreoathetosis and dystonia
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conscious during the episodes of involuntary move-
ments. Unfortunately, she was misdiagnosed as having
psychogenic illness. She had been distressed for many
years until a physician made a correct diagnosis of PKD
at 25 years of age. Treatment with carbamazepine con-
trolled her involuntary movements completely.
Patient 4 (II-3): the father of the patients with BIC
(III-2 and III-3) had no seizures in his infancy. He dis-
played intermittent involuntary movements from the age
of 10 years. The nature of the movement was dystonic.
The attacks were usually triggered by sudden move-
ments or intention to move; for example, when he was
going to take an elevator. The severity of attacks varied
from episodes severe enough to cause him to fall down
to mild episodes that were barely noticed by his friends
and relatives. The attacks were never associated with an
alteration in his level of consciousness. He had been
bothered with involuntary movements for many years.
Finally, he was diagnosed with PKD when his child (III-3)
visited a pediatrician for BIC. His symptoms disappeared
following the start of treatment with carbamazepine.
Patient 5 (II-6): an intellectually disabled man, now
aged 24 years, who had a history of perinatal asphyxia
and surgically repaired tetralogy of Fallot. He presented
with generalized tonic–clonic seizures at 6 years of age.
Although a detailed clinical description of his seizures
was not available, his seizures were under control with
phenobarbital and phenytoin. Family members have oc-
casionally witnessed his dystonic attacks when he forgot
to take medicine. The attacks seemed to be provoked by
sudden voluntary movements and occurred independ-
ently of his habitual seizures. He remained conscious
throughout the dystonic attacks.
After obtaining written informed consent from the
participants, genomic deoxyribonucleic acid (DNA) was
extracted from the peripheral blood leukocytes of each
participant and used as the template for polymerase
chain reaction (PCR). The compatible primers were used
to yield DNA fragments spanning the entire coding region
and intron–exon boundaries of PRRT2. The PCR frag-
ments were analyzed using automated sequencing. The
mutation identified by direct DNA sequencing was further
confirmed by restriction fragment length polymorph-
ism analysis. We identified a PRRT2 missense mutation
(c.981C >G, p.Ile327Met) in two participants with BIC
and three participants with PKD in this family but also in
two unaffected members (Figure 1B and 1C).
Discussion
We report a familial case with a heterozygous mutation
in PRRT2 that has been identified as the causative gene
of PKD. In this family, five individuals had either BIC or
PKD. Although BIC and PKD can occur either aloneor together, no individual had both BIC and PKD. The
PRRT2 missense mutation (c.981C >G, p.Ile327Met) was
identified in two patients with BIC and three patients with
PKD as well as in two unaffected individuals. The same
PRRT2 mutation has been identified in a patient with BIC
without PKD [8]. Allowing incomplete penetrance in the
mutation carriers, this mutation co-segregated completely
with the phenotype. Our results confirmed that two cli-
nically distinct disorders, BIC and PKD, might be allelic
conditions caused by PRRT2 mutation. Taking the tem-
poral changes in the expression of the disease into consid-
eration, we could not exclude the possibility that the
younger patients with BIC, now aged 5 and 7 years, may
develop dyskinesia later in life.
Attacks of PKD and epileptic seizures have several
characteristics in common; both show paroxysmal mo-
tor manifestations and good response to anticonvul-
sants. On the basis of neurophysiological and imaging
studies, a subcortical origin related to basal ganglia is
proposed as being involved in the PKD pathogenesis
[9-11], whereas BIC is relevant to cortical origin [12].
However, the co-occurrence of BIC and PKD in a family
with a PRRT2 mutation suggests that a subset of epilep-
tic seizures may share a common pathogenic mechanism
with PKD. PRRT2 is expressed in brain regions, including
the cerebral cortex and basal ganglia, which were impli-
cated in BIC and PKD, respectively [13]. PRRT2 has been
shown to interact with the synaptosomal-associated pro-
tein of 25 kDa (SNAP25), a presynaptic membrane protein
involved in the synaptic vesicle membrane docking and
fusion pathway [14]. Thus, interaction of PRRT2 with
SNAP25 may play a pivotal role in the regulation of
neurotransmitter release [15]. Such a disturbance of syn-
aptic function may be the common pathogenic mechan-
ism underlying motor manifestations in BIC and PKD.
The mechanism of age-dependent occurrence and remis-
sion of clinical manifestations in BIC and PKD remains to
be elucidated.
Conclusions
Identification of PRRT2 as the causative gene of BIC and
PKD allows genetic confirmation of the clinical diagnosis
as well as genetic counseling to family members. PKD is
often misdiagnosed clinically as epilepsy or psychogenic
illness, which distresses the patients to a great extent.
PKD should be suspected in families with a child with
BIC. A correct diagnosis will improve the quality of life
in patients with PKD because treatment with low doses
of anticonvulsants, such as carbamazepine and phenytoin,
is effective for eliminating the clinical manifestations.
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